Original Publication Date: 1 February, 2015
Publication / Source: Future Oncology
Authors: Peter Gorayski, Bryan Burmeister & Matthew Foote
Cutaneous malignant melanoma remains a significant health burden worldwide despite advances in the management of locoregionally advanced and metastatic disease. Historically, the efficacy of radiation therapy (RT) has been questioned due to the perceived radioresistance of melanoma cancer cells in vitro. Nowadays, RT has limited indications for primary disease, but is used for high-risk nodal disease and in the palliative setting.